Dirk Schadendorf

Complete Loss of Hla Class I Antigen Expression on Melanoma Cells: a Result of Successive Mutational Events Publication of the International Union against Cancer

D. Schadendorf, F. Garrido, A. Sucker, 2022 .

Patterns of constitutive and IFN-γ inducible expression of HLA class II molecules in human melanoma cell lines

D. Schadendorf, G. Pawelec, F. Garrido, 2007, Immunogenetics.

Proteasome inhibition potentiates Kv1.3 potassium channel expression as therapeutic target in drug-sensitive and -resistant human melanoma cells.

A. Paschen, Theresa Lowinus, Clemens Cammann, 2023, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

Charles J. Vaske, Rohan N. Borkar, David M. Schauder, 2016, Journal for ImmunoTherapy of Cancer.

Final results of urelumab, an anti-CD137 agonist monoclonal antibody, in combination with cetuximab or nivolumab in patients with advanced solid tumors

N. Segal, J. Neely, S. Suryawanshi, 2024, Journal for ImmunoTherapy of Cancer.

Recombinant adeno-associated virus for the generation of autologous, gene-modified tumor vaccines: evidence for a high transduction efficiency into primary epithelial cancer cells.

D. Schadendorf, R. Kotin, M. Hallek, 1998, Human gene therapy.